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Abstract
Glucagon-like peptide 1 (GLP-1) is known to stimulate insulin secretion and
biosynthesis, but has also been shown to decrease insulin requirements in type
1 diabetic subjects suggesting insulin-independent effects. To assess whether
GLP-1 exerts also direct effects on whole-body glucose metabolism, 6,6-D2-
glucose kinetics were measured in 8 healthy volunteers receiving once GLP-1,
once saline during hyperglycemic glucose clamping, while somatostatin with
replacement amounts of insulin, glucagon and growth hormone was infused.
Even though endogenous insulin secretion could not be blocked completely
(increased plasma concentrations of C-peptide and proinsulin), somatostatin
infusion resulted in stable insulin and glucagon plasma levels in both protocols
(GLP-1 vs. placebo: NS). After 3 h of GLP-1 infusion, peripheral glucose dis-
appearance significantly increased compared to placebo (p ! 0.03) despite of
somatostatin-induced suppression of insulin and glucagon secretion. Thus,
GLP-1 infusion seems to have direct stimulatory effects on peripheral glucose
metabolism in man.
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Introduction
The incretin glucagon-like peptide 1, GLP-1 (7–36
amide) is known to stimulate insulin secretion from the
pancratic ß-cell [1]. This insulinotropic activity is highly
glucose dependent [2], suggesting no risk for hypoglyce-
mia during administration of this peptide. In addition,
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dation (No. 32-39747.93) and the ‘Wissenschaftliche Kredit’, University Hos-
pital Basel. A.S. is a recipient of grants from the Postgraduate Course in Experi-
mental Medicine and Biology (Swiss National Science Foundation), from the
‘Freiwillige Akademische Gesellschaft’ and from ESPEN-Ajinomoto.
GLP-1 activates proinsulin gene transcription, augments
the rate of insulin gene expression and maintains the rate
of insulin biosynthesis [3]. Administration of synthetic
GLP-1 to healthy volunteers has been demonstrated to
decrease hepatic glucose output [4]. In non-insulin-depen-
dent (type 2) diabetic subjects, GLP-1 infusion has been
shown to induce insulin and C-peptide secretion and to
decrease glucagon release [5]. All these effects can easily
be explained by an increase in plasma insulin concentra-
tions caused by GLP-1 infusion. However, since GLP-1
administration was able to reduce insulin requirements in
C-peptide-deficient, insulin-dependent (type 1) diabetic
subjects [6], this peptide might also have an insulin-inde-
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pendent activity of its own. This hypothesis is supported
by the enhanced glucose effectiveness (insulin-indepen-
dent glucose disposal) observed during GLP-1 infusion in
healthy man [7] and by in vitro studies suggesting a gly-
cogenic effect of GLP-1 in skeletal muscle [8].
The present study addressed the question whether
GLP-1 infusion has also direct effects on whole-body glu-
cose metabolism. To overcome GLP-1-induced hormonal
changes, somatostatin was infused during all studies,
while insulin, glucagon and growth hormone were re-
placed in basal amounts (pancreatic clamp) [9]. Glucose
clamping was performed at 8 mmol/l taking into account
the glucose dependence of GLP-1 effects and imitating
mild hyperglycemia during restricted insulin availability.
Subjects and Methods
Subjects
Eight healthy male volunteers with a body mass index of 22 B 1
kg/m2 and a mean age of 25 B 1 years gave their written informed
consent to participate. For the last 2 weeks before the study, their
body weight had been stable and they had not been on a diet or taking
any drugs. The study protocol was approved by the Human Ethics
Committee, Department of Medicine, University of Basel. Every
volunteer was studied twice, with an interval of at least 1 week, once
with GLP-1 and once with placebo (saline), in randomized order.
Procedures
At 8 a.m. after a 12-hour overnight fast, a Teflon cannula was
inserted into an antecubital vein, and blood samples were obtained to
assess background plasma enrichments of 6,6-D2-glucose. A priming
dose of 6,6-D2-glucose (16.6 Ìmol/kg; 98% enriched, sterile and
pyrogen free, Mass Trace, Woburn, Mass., USA) was injected. There-
after 6,6-D2-glucose was infused at 0.22 Ìmol ! kg–1 ! min–1. A
butterfly needle was inserted retrogradely into a dorsal hand vein for
withdrawal of arterialized blood [10] while the hand was kept in a
heated box at 57 °C. After a 2-hour equilibration period for the stable
labeled isotope, blood samples were obtained during a 30-min base-
line period. Thereafter, continuous infusions of somatostatin (90 ng
! kg–1 ! min–1; Stilamin, Serono, Aubonne, Switzerland), insulin
(0.87 pmol ! kg–1 ! min–1; Actrapid HM, Novo, Bagsvaeard, Den-
mark), glucagon (0.2 ng ! kg–1 ! min–1; GlucaGen, Novo) and
recombinant human growth hormone (6 ng ! kg–1 ! min–1; Geno-
tropin, kindly provided by Pharmacia, Dübendorf, Switzerland)
were started. This dose of somatostatin was at the limit of tolerance –
nausea (without vomiting) occurred in 4 of 16 studies. After 30 min
an infusion of synthetic GLP-1 (7–36 amide; 1.2 pmol ! kg–1 !
min–1; sterile and pyrogen free, net peptide content 91.68%, peptide
purity 197%, Saxon Biochemicals, Hannover, Germany) or of place-
bo (NaCl 0.9% w/v) was commenced and continued for 180 min.
This pharmacological infusion rate of GLP-1 has been used previous-
ly [5]. Immediately before administration, GLP-1, somatostatin and
the other hormones were mixed in saline in 50-ml syringes with 2 ml
of a subject’s own blood in order to prevent adsorption of the hor-
mones to surfaces. During the infusion period hyperglycemia of
8 mmol/l was achieved and maintained by a glucose infusion (20%
w/v). The infusion rate was frequently adjusted depending on the
actual plasma glucose level. The variable glucose infusion was
enriched to 1.5% with 6,6-D2-glucose in order to prevent an underes-
timation of the rate of hepatic glucose production [11]. Plasma glu-
cose concentrations were measured in 5- to 10-min intervals using a
glucose oxidase method (Yellow Springs Glucose Analyzer model 23
AM; Yellow Springs, Ohio, USA) [12].
Analyses and Calculations
Plasma samples were analyzed for 6,6-D2-glucose tracer/tracee
ratio (TTR; D2-labelled/unlabelled glucose) using a gas chromato-
graph-mass spectrometer (Hewlett Packard Mod. 5890/5970, Palo
Alto, Calif., USA). The glucose derivative was (2,3,4,5,6)-pentakis-
O-trimethylsilyl-O-methyloxime-D-glucose, and the masses used for
the mass-spectrometric measurements of labelled and unlabelled glu-
cose were 321 and 319, respectively [13]. Glucose rate of appearance
equalled glucose rate of disappearance (Rd) since steady state condi-
tions were present during baseline and during the last 30 min of the
infusion period as D2-glucose TTR did not change over time
(ANOVA with repeated measures). Due to the enrichment of the
variable glucose infusion, the TTR did not decrease over the whole
period of time. Rd as a measure of peripheral glucose utilization was
calculated by dividing the D2-glucose infusion rate by the D2-glucose
TTR. Division of Rd by plasma glcuose concentration yielded the
metabolic clearance rate of glucose (MCR). Hepatic glucose output
(HGO) was computed by subtracting the total glucose infusion rate
from the glucose rate of appearance [14]. D2-background enrich-
ments were subtracted from all corresponding plasma values. Plasma
concentrations of insulin, proinsulin, C-peptide and glucagon were
measured by radioimmunoassays [INSIK-5 (P2796), SORIN Bio-
medica, Saluggia, Italy; coefficient of variation, CV: 8.2%; human
proinsulin, LINCO Research, St. Charles, Mo., USA; C-PEP-CT2,
CIS Bio International, France (CV 5.8%; cross-reactivity with proin-
sulin 13%; no detectable cross-reactivity with GLP-1) and glucagon
double antibody, Diagnostic Products, Bühlmann Laboratories, Ba-
sel, Switzerland (CV 8.7%), respectively]. The software STATVIEW
(Macintosh) was used for statistical analyses. Effects of protocol and
time were assessed by repeated measures ANOVA. Paired t tests
were performed to compare differences between the two protocols.
Results are expressed as means B SEM.
Results
Glucose Kinetics
During hyperglycemic clamping, plasma glucose con-
centrations increased rapidly and remained at 8.0 B 0.1
mmol/l for the last 2 h in both protocols (fig. 1). The glu-
cose infusion rates (GINF) required for maintaining plas-
ma glucose at 8 mmol/l were 75% higher during the last
120 min of GLP-1 infusion than during placebo (p !
0.02). Rd (fig. 2a) increased from 14.6 B 0.9 during the
basal period to 24.2 B 2.2 Ìmol ! kg–1 ! min–1 during
the last 30 min of GLP-1 infusion (infusion vs. basal peri-
od: p ! 0.001) compared to placebo from 13.8 B 0.8 to
17.2 B 2.1 Ìmol ! kg–1 ! min–1 (infusion vs. basal peri-
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Fig. 1. Plasma glucose concentrations (lines) during baseline (–30
to 0 min) and during pancreatic and hyperglycemic clamping (30–
210 min) in 8 healthy subjects receiving GLP-1 or saline infusion and
the required glucose infusion rate (GINF; bars) for maintaining plas-
ma glucose at 8 mmol/l. Means B SEM; GLP-1 vs. placebo: plasma
glucose levels (NS); GINF (p ! 0.02).
od: NS; GLP-1 vs. placebo: p ! 0.03). MCR (fig. 2b) aug-
mented during GLP-1 administration from 2.81 B 0.16
to 3.05 B 0.29 ml ! kg–1 ! min–1. During placebo MCR
slightly decreased from 2.70 B 0.18 to 2.16 B 0.27 ml !
kg–1 ! min–1 (GLP vs. placebo: basal: NS; clamp: p !
0.03). During the hyperglycemic clamp of the GLP-1 pro-
tocol, HGO decreased from baseline to 25 B 5% (from
14.40 B 0.94 to 3.61 B 0.78 Ìmol ! kg–1 ! min–1;
clamp vs. basal: p ! 0.0001) and during placebo to 52 B
6% (from 13.54 B 0.85 to 7.01 B 0.82 Ìmol ! kg–1 !
min–1; clamp vs. basal: p ! 0.0001; GLP-1 vs. placebo: p !
0.01; fig. 2c).
Plasma Hormone Concentrations
Plasma insulin concentrations (fig. 3) remained at high
basal level during the 210 min of combined infusion of
somatostatin, insulin, glucagon and growth hormone. In
spite of slightly increased levels at the end of the GLP-1
infusion, insulin concentrations were not significantly dif-
ferent between GLP-1 and placebo at any time during
pancreatic clamping. However, during the 3-hour GLP-1
infusion, the plasma concentrations of C-peptide and
proinsulin increased from 474 B 33 (basal) to 634 B 107
and from 7.3 B 0.5 to 16.5 B 2.5 pmol/l, respectively,
whereas C-peptide and proinsulin levels decreased from
basal 447 B 46 to 65 B 10 and from 6.1 B 0.5 to 3.1 B
Fig. 2. Effects of GLP-1 or saline infusion on Rd (a), MCR (b)
and HGO (c) in 8 healthy subjects, as assessed by 6,6-D2-glucose
kinetics during baseline (–30 to 0 min) and during the last 30 min of
pancreatic and hyperglycemic clamping (180–210 min). Means B
SEM. * p ! 0.03, GLP-1 vs. placebo.
0.3 pmol/l, respectively, during saline infusion (GLP-1 vs.
saline: p ! 0.002 and p ! 0.03, respectively). Glucagon
plasma levels remained unchanged by GLP-1 and saline
infusion (15.9 B 2.6 and 17.3 B 1.5 pmol/l, respectively;
GLP-1 vs. saline: NS).
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Fig. 3. Effects of GLP-1 or saline infusion on plasma concentra-
tions of insulin in 8 healthy subjects (baseline –30 to 0 min; somato-
statin infusion 0–210 min and hyperglycemic infusion period 30–
210 min). Means B SEM. GLP-1 vs. placebo: NS.
Discussion
In the present study, somatostatin infusion resulted in
stable plasma glucagon levels throughout the experiment
during both GLP-1 and saline infusion. Somatostatin also
induced a marked suppression of insulin secretion (during
GLP-1 infusion, plasma concentrations of insulin were 15
times lower than without somatostatin [15]).
Despite somatostatin-induced suppression of glucagon
and insulin secretion, GLP-1 administration resulted in
an increased rate of peripheral glucose disappearance
suggesting, at least in part, a direct peripheral effect of
GLP-1. A difference of 7 Ìmol ! kg–1 ! min–1 in Rd as
found in the present study between GLP-1 and placebo
has been observed only during an increase in plasma insu-
lin concentrations of 180 pmol/l [16]. However, in the
present study, measured plasma insulin levels differed by
30 pmol/l at the most between the two protocols. Al-
though this amount of insulin could contribute to the
observed changes in Rd, it is unlikely. Even to reduce the
more insulin-sensitive HGO by 50% as demonstrated in
the present study, an increase in plasma insulin of more
than 50% would be necessary [16]. However, it is possible
that increased insulin concentrations in the portal system,
undetected in peripheral blood, were involved in this
hepatic effect. The HGO decrease in the placebo group
can be explained by the hyperglycemia present in both
protocols.
C-peptide is known to be metabolically inactive [17],
whereas proinsulin-mediated glucose disposal has been
shown to be 7% that of insulin on a molar basis [18]. Con-
sequently, the proinsulin increase during the GLP-1 infu-
sion of 9.2 pmol/l would have the same effect as an
increase in plasma insulin by 0.6 pmol/l, a rather negligi-
ble amount. Taken together, the increase in insulin pre-
cursors in the circulation cannot account for the observed
changes in glucose metabolism.
The suggested direct effects of GLP-1 on peripheral tis-
sue, i.e. skeletal muscle (Rd), are in agreement with in
vitro experiments describing direct glycogenic effects of
GLP-1 on rat skeletal muscle [8] and can explain, at least
in part, the glucose-lowering effects of GLP-1 observed in
type 1 diabetic patients [6].
In conclusion, the present results suggest that besides
its known insulinotropic activity the incretin GLP-1 has
metabolic effects influencing peripheral glucose metabo-
lism in humans. Further studies in insulin-dependent
C-peptide-deficient diabetic patients are necessary in or-
der to confirm the therapeutical significance of these find-
ings.
Acknowledgments
We would like to thank Ms. S. Vosmeer, Ms. K. Dembinski and
Mr. N. Sansano for excellent technical assistance.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 2
:2
6:
54
 P
M
Glucose Kinetics during GLP-1 and
Somatostatin Infusion in Men
Horm Res 1998;49:221–225 225
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO
References
1 Holst JJ, Orskov C, Nielsen OV, Schwartz TW:
Truncated glucagon-like peptide I, an insulin-
releasing hormone from the distal gut. FEBS
Lett 1987;211:169–174.
2 Göke R, Wagner B, Fehmann HC, Göke B:
Glucose-dependency of the insulin stimulatory
effect of glucagon-like peptide-1 (7–36) amide
on the rat pancreas. Res Exp Med (Berl) 1993;
193:97–103.
3 Fehmann HC, Habener JF: Insulinotropic hor-
mone glucagon-like peptide-1 (7–37) stimula-
tion of proinsulin gene expression and proinsu-
lin biosynthesis in insulinoma beta TC-1 cells.
Endocrinology 1992;130:159–166.
4 Hvidberg A, Nielsen MT, Hilsted J, Orskov C,
Holst JJ: Effect of glucagon-like peptide-1 (pro-
glucagon 78–107 amide) on hepatic glucose
production in healthy man. Metabolism 1994;
43:104–108.
5 Nauck MA, Kleine N, Orskov C, Holst JJ,
Willms B, Creutzfeldt W: Normalization of
fasting hyperglycaemia by exogenous glucagon-
like peptide 1 (7–36 amide) in type 2 (non-insu-
lin-dependent) diabetic patients. Diabetologia
1993;36:741–744.
6 Gutniak M, Orskov C, Holst JJ, Ahren B, Efen-
dic S: Antidiabetogenic effect of glucagon-like
peptide-1 (7–36) amide in normal subjects and
patients with diabetes mellitus. N Engl J Med
1992;326:1316–1322.
7 D’Alessio DA, Kahn SE, Leusner CR, Ensinck
JW: Glucagon-like peptide 1 enhances glucose
tolerance both by stimulation of insulin release
and by increasing insulin-independent glucose
disposal. J Clin Invest 1994;93:2263–2266.
8 Villanueva PM, Alcantara AI, Clemente F,
Delgado E, Valverde I: Potent glycogenic effect
of GLP-1 (7–36) amide in rat skeletal muscle.
Diabetologia 1994;37:1163–1166.
9 Hood VL, Keller U, Haymond MW, Kury D:
Systemic pH modifies ketone body production
rates and lipolysis in humans. Am J Physiol
1990;259:E327–E334.
10 Abumrad NN, Rabin D, Diamond MP, Lacy
WW: Use of heated superficial hand vein as
alternative site for the measurement of amino
acid concentrations and for the study of glucose
and alanine kinetics in man. Metab Clin Exp
1981;30:936–940.
11 Molina JM, Baron AD, Edelman SV, Brechtel
G, Wallace P, Olefsky JM: Use of a variable
tracer infusion method to determine glucose
turnover in humans. Am J Physiol 1990;258:
E16–E23.
12 DeFronzo RA, Tobin JD, Andres R: Glucose
clamp technique: A method for quantifying
insulin secretion and resistance. Am J Physiol
1979;237:E214–W223.
13 Kuery D, Keller U: Trimethylsilyl-O-methylox-
ime derivatives for the measurements of (6,6-
2H2)-D-glucose-enriched plasma samples by
gas chromatography-mass spectrometry. J
Chromatogr 1991;572:302–306.
14 Cobelli C, Toffolo G, Bier DM, Nosadini R:
Models to interpret kinetic data in stable iso-
tope tracer studies. Am J Physiol 1987;253:
E551–E564.
15 Nauck MA, Heimesaat MM, Orskov C, Holst
JJ, Ebert R, Creutzfeldt W: Preserved incretin
activity of glucagon-like peptide 1 (7–36 am-
ide) but not of synthetic human gastric inhibi-
tory polypeptide in patients with type-2 dia-
betes mellitus. J Clin Invest 1993;91:301–307.
16 Rizza RA, Mandarino LJ, Gerich JE: Dose-
response characteristics for effects of insulin on
production and utilization of glucose in man.
Am J Physiol 1981;240:E630–E639.
17 Polonsky KS, Rubenstein AH: The kinetics
and metabolism of insulin, proinsulin, and C-
peptide; in DeGroot LJ (ed): Endocrinology.
Philadelphia, Saunders, 1989, vol 2, pp 1304–
1317.
18 Revers RR, Henry R, Schmeiser L, Kolterman
O, Cohen R, Rubenstein A, Frank B, Galloway
J, Olefsky JM: Biosynthetic human insulin and
proinsulin have additive but not synergistic
effects on total body glucose disposal. J Clin
Endocrinol Metab 1984;58:1094–1098.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 2
:2
6:
54
 P
M
